Lilly adds potential first-in-class Type II JAK2 inhibitor to haematology portfolio

2026-04-28T10:04:00

polycythemia vera blood concept

Source:

The pharmaceutical company’s $2.3 billion acquisition of Ajax Therapeutics set to advance outcomes for myeloproliferative neoplasms.

Eli Lilly has confirmed a second major acquisition this month, now agreeing to pay US-based biopharmaceutical company Ajax Therapeutics up to $2.3 billion, for its potential first-in-class Type II JAK2 inhibitor.

Ajax’s oral candidate, AJ1-11095, is currently being evaluated in a Phase I clinical trial, AJX-101, in those with myelofibrosis previously treated with a Type I JAK2 inhibitor. While these JAK2 inhibitors provide clinical relief, many patients often discontinue treatment due to a lack of durable benefit or loss of response.

However, AJ1-11095 could deliver

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member